PHARMACOLOGICAL ACTION OF DEFLAZACORT: A REVIEW

1Neha Sharma, 2Punam Gaba, 3Shilpa Kumara

1Post graduation student, 2Assistant Professor, 3Post graduation student
1Department of Pharmaceutics
1Amar Shehba Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela Ropar Punjab 140111, India

ABSTRACT: Deflazacort comes under the category of BCS class II and this drug is an immunosuppressant and anti-inflammatory drug which is a corticosteroid prodrug various parameters have been studied such as related to the introduction of the drug, various name of drug in different countries and the history of the drug and its origin parts related to chemistry such as structure, molecular weight, IUPAC and regarding to the pharmacology various parameters of pharmacokinetics. Studies on rats, however, showed that the medication had high levels in the liver and kidneys, medium levels in the cardiac, pancreas, pulmonary, and submaxillary glands, low levels in articular cartilage, striated muscle, the spleen, the gonads, and the thymus, and extremely low levels in the brain. The area under the time vs. plasma concentration curve, the half-life, and the total bioavailability via oral ingestion. Detailed pharmacodynamics properties like mechanism of action of deflazacort was studied which explain how the hormone bind to the receptor and show its anti-inflammatory and immunomodulatory effect impact on the mononuclear cells and impact on glucose metabolism were studied that include absorption, distribution, metabolism, excretion, half-life of the drug, mechanism of action, various therapeutic action have been checked out related to the rheumatoid arthritis, and related to the chronic juvenile arthritis, Asthma and Other Airways Diseases, Nephrotic Syndrome. Tolerability and oral dosage administration. The reference glucocorticoid prednisone has a suggested dosage range of. Deflazacort is less powerful than prednisone and is frequently given in larger proportions. In general, investigations to evaluate the dose equivalent of deflazacort and prednisone discovered that deflazacort was less powerful than prednisone, resulting in a dosage ratio. Despite these drawbacks, deflazacort showed comparable effectiveness to prednisone and methylprednisolone in treating rheumatoid arthritis, as well like prednisone in treating individuals with nephrotic syndrome.

KEYWORDS: Deflazacort, corticosteroid, chemistry, rheumatoid arthritis, and glucocorticoid.

INTRODUCTION

Deflazacort is a prednisolone oxazoline derivative having anti-inflammatory and immunosuppressive properties. Either immediate (4 to 6 weeks) and over time (13 to 52 weeks) studies have shown that deflazacort is just as effective as prednisone or methylprednisolone in treating rheumatoid arthritis. In youngsters with juvenile chronic arthritis, the medication proved at least as effective as prednisone. Deflazacort has demonstrated some effectiveness in treating kidney disease and other use, including Duchenne dystrophy, chronic lupus erythematosus, uveitis, and transplantation. However, there is insufficient data to make clear judgements about the drug’s effectiveness in managing chronic asthma.

The total number of negative reactions in deflazacort consumers (6.5%) is comparable to that seen in betamethasone (5.3%) consumers and less than that in consumers of prednisone (20.5%) or methylprednisolone (32.7%). Symptoms of the intestinal tract are the side effects of deflazacort that are most often recorded; other side effects linked to the treatment include metabolism and dietary deviations changes of the nervous systems in the body, and mental health conditions. In contrast to prednisone, deflazacort frequently seems to have lower of an impact on indicators linked to the onset of corticosteroid-induced osteoporosis. Additionally, it seems that among kids with diseases that call for corticosteroid therapy, the medication has a less negative effect on their rate of development.

Moderate doses of deflazacort produced no clinically meaningful diabetogenic effects in a 2-month investigation of patients with illnesses needing corticosteroid treatment. Therefore, deflazacort might have less apparent hepatic negative consequences than prednisone, but more thorough, lengthy investigations are required to confirm this.

In the meanwhile, deflazacort should be reserved for people who are prone to or experience unacceptable metabolic consequences after corticosteroid treatment. In youngsters, however, despite the lack of efficacy data, considering the negative effects of this kind of medication tend to be particularly debilitating in this patient group, deflazacort should be investigated as an initial alternative in individuals requiring corticosteroid therapy.

Deflazacort, also known as Calcort, is a corticosteroid it is as an example anti-inflammatory and immune modifying agent. It was invented in 1965 and first used in medicine in 1985. [2] The United States Food And drug (FDA) of the United States considers it another medicine for Duchenne Myopathy.[3]

Marathon Pharmaceuticals was bestowed fast track done by the Food and drug administration in January 2015 to undertake authorization of deflazacort as a possible therapy for Duchenne muscular dystrophy, a peculiar, “accelerated and deadly disease” that affects boys.[4] Although the FDA approved deflazacort for the therapies of Duchenne muscular dystrophy on Feb. 9, 2017,[5] [6]
Marathon CEO confirmed on February 13, 2017, that the introduction of deflazacort (Emflaza) will be retarded due to complaints over the high price Marathon had been charging for the treatment in the US – $89,000 per year, meaning "approximately 70 times" what it was going to cost abroad. [7] Because deflazacort is an older drug that has long been approved in another nations, it is now widely available as a low-cost generic. In Canada, for example, deflazacort costs about $1 per tablet. [8] On the sixteenth of March 2017, PTC Therapeutics, Inc. secured the rights to Emflaza and started marketing it in the United States of America under the company's name Emflaza.

Table :1 deflazacort name in different countries:

<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>BRAND NAME</th>
</tr>
</thead>
<tbody>
<tr>
<td>United state</td>
<td>Emflaza</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>Calcort</td>
</tr>
<tr>
<td>Brazil</td>
<td>Cortax, Defcort, Deflanil, Decortil</td>
</tr>
<tr>
<td>India</td>
<td>Moaid, Zenflav, Defolet, DFZ, Decotaz, Defzot</td>
</tr>
<tr>
<td>Bangladesh</td>
<td>Xalcort</td>
</tr>
<tr>
<td>Panama</td>
<td>Zamen</td>
</tr>
<tr>
<td>Spain</td>
<td>Zamene</td>
</tr>
<tr>
<td>Honduras</td>
<td>Flexacor</td>
</tr>
</tbody>
</table>

The FDA has endorsed deflazacort to treat people aged five and up who have Duchenne muscular dystrophy (DMD), a genetic condition that caused severe muscle degradation and loss of strength. Emflaza is a glucocorticoid that works by reducing inflammation and immunological activity. [11] On February 9, 2017, NDA 208684 was approved as a Type 1 novel molecular entity with orphan status.[12]

Drug profile

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Deflazacort</th>
</tr>
</thead>
<tbody>
<tr>
<td>Structure</td>
<td><img src="image.png" alt="Image" /></td>
</tr>
<tr>
<td>IUPAC (International union of pure and applied chemistry)</td>
<td>(11β,16β)-21-(Acetyloyxy)-11-hydroxy-2'-methyl-5'H-pregna-1,4-dieno[17,16-d] oxazole 3,20-dione</td>
</tr>
<tr>
<td>Chemical formula</td>
<td>C25H31NO6</td>
</tr>
<tr>
<td>Molecular weight</td>
<td>441.5</td>
</tr>
<tr>
<td>Melting point</td>
<td>252-256°C</td>
</tr>
<tr>
<td>Log P</td>
<td>2.4</td>
</tr>
</tbody>
</table>
PHARMACOLOGICAL DETAIL:

1. Detailed Pharmacodynamic Properties

Studies conducted in vitro have shown that deflazacort drastically decreases human blood circulation mononuclear cell growth and the release of particular cytokines from these cells. A significant reduction in CD4+ cells was found following medication exposure (15mg given prior to cell harvest), but an approximate rise in the CD8+ group was seen. Prednisone (12.5mg introduced before cell harvest) showed similar, albeit less prolonged, effects in the same experiment. Deflazacort was prescribed to rheumatoid arthritis (RA) sufferers just before the collection of their synovial fluid for analysis, which resulted in a decline in CD4+ clones and a reversal of the ratio of CD3+CD4+ to CD3+CD8+ clones. The development of the anion superoxide, chemiluminescence, and chemotaxis was additionally inhibited in vitro using human polymorphonuclear leucocytes.

Deflazacort 36mg delivered 12 and 2 hours after dietary glucose tolerance examination had less of a negative effect on the absorption of glucose in individuals with family histories of non-insulin-dependent diabetes mellitus than prednisone 30mg introduced in a comparable manner. In a longer-term (2 month) traverse research, moderate dosages of deflazacort [30 to 50 mg/day] and betamethasone [2 to 4 mg/day] did not have a clinically relevant diabetogenic influence in patients with illnesses requiring corticosteroid remedy. At larger doses, betamethasone was more effective than deflazacort affecting the breakdown of glucose.

Mechanism of action of deflazacort:

Deflazacort

Binds to glucocorticoid receptor

In the cytoplasm causes confirmational changes in glucocorticoid receptor

The steroid receptor complex become activated

Enter the nucleus

GR complex binds to specific DNA chronology called glucocorticoid response element

Modulate gene transcription

Increase declaration of anti-inflammatory protein for e.g., lipocortin-1

Decreases expression of pro-inflammatory protein for e.g., cytokines

Induce apoptosis of certain immune cell

Inhibit release and other mediator from the mast cell

Inhibit the migration of leucocytes

1.1 Immuno-modulatory effects:

All immune system cells are impacted by glucocorticoids, which also have an impact on lymphocyte distribution, proliferation, differentiation, and function. neutrophils and monocytes. Generally speaking, glucocorticoids inhibit the formation of interleukin (IL) -2, IL-4, IL-6, interferon-gamma, and tumour necrosis factor, down-regulate the expression of the major histocompatibility complex gene products, and cause the programmed death of activated lymphocytes (reviewed in Scudeletti et al. [41]). Deflazacort has been demonstrated to specifically suppress IL-1-stimulated IL-6 generation from human chondrocytes and osteoblast-like cells in a concentration-dependent manner. [5]

1.1.1 Impact on Mononuclear Cell

In vitro, deflazacort strongly reduces phytohemagglutinin (PHA)-induced proliferation of human peripheral blood mononuclear cells (HPBMC) [6,7] and has been found to reduce IL-2, soluble IL-2 receptor, and IL-6 production by HPBMC exposed to PHAP. The magnitude of these effects is concentration dependent. In one study, the depressant effect of deflazacort (15mg administered 6 hours before cell harvest) on PHA-induced human T lymphocyte proliferation was comparable to that of prednisone (12.5mg administered 6 hours before cell harvest), but it lasted longer (48 vs 24 hours). A significant decrease in CD4+ cells was also

<table>
<thead>
<tr>
<th>Water solubility</th>
<th>108µg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pka</td>
<td>5.52</td>
</tr>
</tbody>
</table>
detected, accompanied by an increase in the CD8+ fraction; once again, deflazacort exhibited a more persistent effect than prednisone. [8]

The effects of deflazacort and prednisone (administered prior to sampling) on lymphocytes cloned from samples gained using the synovial fluid (SF) of arthritis with rheumatoid disease patients. Also studied to determine whether corticosteroid therapy has similar effects on lymphocytes involved in autoimmune disease processes. A decrease in CD4+ clones was seen, along with a shift in the ratio of CD3+CD4+ to CD3+CD8+ clones. Furthermore, deflazacort was linked to a considerable decrease in the number of CD2+ and IL-2 receptor positive clones. Other surface marker-expressing clones were unaffected (reviewed by Scuderi et al. [9]. Deflazacort strongly decreased human polymorphonuclear leucocyte. In a second in vitro research, chemotherapy, the production of superoxide anion generation, and luminescence, or were observed. [10]

1.2 Impact on Glucose Metabolism

Response to supraphysiological glucocorticoid levels generates a diabetic-like state’ fasting plasma glucose levels tend to be high, insulin resistance increases, glucose tolerance decreases, and glucosuria may be caused (reviewed by Haynes [11]). Importantly, the degree of this effect appears to be stronger during short-term treatment and to diminish slightly after long-term administration; the effect is also greater in patients with already present intolerance to glucose.[11]

In a short-term investigation involving individuals with a family history of diabetes without insulin dependence (2 doses of deflazacort 36mg vs prednisone 30mg) [12] and a longer-term study of patients with overt diabetes (4 weeks' therapy with deflazacort 30 mg/day vs prednisone 25 mg/day). Insulin needs remained close to baseline (28.5 U/day) in deflazacort receivers but increased to 46.3 U/day in prednisone patients (p 0.001 vs deflazacort). [13] Bruno et al. [14] investigated the longer term (2 month) effects of deflazacort on glucose metabolism against those of betamethasone in 27 individuals with diseases requiring glucocorticoid medication in a randomised crossover research (without an intertreatment washout interval).

Neither drug showed a clinically relevant diabetogenic impact at intermediate dosages (deflazacort 30 to 50 mg/day; betamethasone 2 to 4 mg/day); above these dosage levels, betamethasone influenced glucose metabolism more than deflazacort. The only statistically substantial distinction that exists between treatments at the end-point was a higher rise in the top of the insulin level in the blood vs time line (4% after deflazacort vs 34% after betamethasone).

The last of these three studies is likely to be more therapeutically relevant because it was conducted over a longer length of time and the dosages of both medications were titrated to effect rather than supplied as fixed doses in a predetermined ratio.

Pharmacokinetic properties:

Deflazacort's key component, deflazacort-21-hydroxide, attained a peak bloodstream blood level of 121 g/l0.96 hours after being given as just one mouth dose of 30 mg to 12 volunteers. It was a 68% average bioavailability when taken by mouth. The time vs. plasma level curve's area under the curve and half-life of the were 1.81 and 381 g/lh, accordingly. Deflazacort has not been studied in people; however, both the kidneys and liver of rats were shown to contain the highest concentrations of the drug. A radio-labelled dose of deflazacort was eliminated by three human volunteers (n = 3) in their stool and by 68.4% of them in urine.

There aren't much pharmacokinetic data available for deflazacort. Deflazacort is deacetylated at the 21 positions after injection, resulting in deflazacort 21-hydroxide, the active ingredient. The pharmacokinetic parameters of this metabolite that were determined after volunteers were given single intravenous or oral doses of deflazacort 30mg in a crossover fashion. 68% [15] was the total oral bioavailability. After giving a 50mg dose of the medication to 3 volunteers. 39.8% of the medication was bound to plasma proteins.[16] Regarding the distribution of deflazacort in human tissues, no information is provided. Studies on rats, however, showed that the medication had high levels in the liver and kidneys, medium levels in the circulatory system, the pancreatic lungs, and submaxillary glands have high levels, while cartilaginous tissue, striated muscle, the spleen, gonads, and thymus have low levels, and the brain has low levels at all times.[16]

Deflazacort's radioactive test dose was eliminated in two ways in three volunteers: through the kidneys (68.4%) and through the stool (30.7%) [16] As previously mentioned, the drug undergoes C-21 deacetylation as its primary metabolic destiny, followed by 6β hydroxylation, reduction of the ring A and the C-30 keto group, and oxidation of the 11-hydroxy function. The main metabolite of deflazacort 21-hydroxy was identified in plasma, but the main metabolite in urine was the 6β derivatives.[17]

Therapeutic use:

Deflazacort determined to be as useful as methylprednisolone in individuals with rheumatoid arthritis in quick-time studies (four to six weeks) in small affected person corporations. Furthermore, diverse longer-time (thirteen to fifty two-week) randomised research comparing the efficacy of deflazacort with prednisone or methylprednisolone in this patient institution were carried out. All said that deflazacort progressed rheumatoid arthritis signs and symptoms and became as powerful as the comparator medication (prednisone or methylprednisolone) on this regard. The handiest comparison trial in youngsters with juvenile chronic arthritis found that deflazacort receivers had a higher discount in mean simple joint be counted (22 at baselyelve vs 17.1 after 12 months) than prednisone recipients (15 at baseline vs 15 after 12 months).

The usefulness of deflazacort as a remedy for asthmatic has only been tested in just a handful of examinations, and the studies that were undertaken mostly aimed to determining the dosage equivalents of deflazacort and prednisone; the clinical effectiveness was a second end-point. A total of three phases were involved in the larger of the two investigations assessing deflazacort and prednisone in asthma sufferers. The pulmonary function indices of deflazacort receivers decreased whereas those of prednisone patients enhanced throughout the final phase (12 weeks). Another study compared deflazacort and prednisone for their effectiveness in treating flare-ups of long-term asthma. Deflazacort 30 or 60 mg and prednisone 30 or 50 mg were both administered at a high starting dose that was subsequently decreased over a period of 15 to 18 days.
According to the findings of two small early investigations, deflazacort improved airway blockage in sufferers suffering from chronic obstructive pulmonary disease. In several trials having prednisone, deflazacort shown some effectiveness as a treatment for adults and kids with nephrotic syndrome. There have been studies on carcinoma of the breast, vital combined cryoglobulinemia, the condition Duchenne dystrophy, safeguarding residual islet cell role in patients with current onset insulin-dependent diabetes mellitus, systemic lupus erythematosus, sarcoidosis, thrombocytopenic purpura, after the transplantation of organs, and uveitis. Deflazacort was superior relative to placebo in placebo-controlled studies and was as successful compared to the comparator drug.

3.1 Rheumatoid Arthritis
Nonsteroidal anti-inflammatory medicines (NSAIDs) are the first line of medical therapy for rheumatoid arthritis patients; corticosteroids are only introduced after NSAID monotherapy fails to control the condition. The conclusion that follows is that only those with more severe candidates for corticosteroid treatment include diseases. The main justification for glucocorticoid reserve their propensity to have detrimental effects that are so severe that they require second-line treatment. Although data from numerous trials assessing the effectiveness of deflazacort in people with rheumatoid arthritis are available, many of these studies only involved a limited number of participants and were too short in duration to thoroughly evaluate the drug’s effectiveness. In patients with active inflammatory rheumatoid arthritis (n = 14[18] or 16[19]; duration 4[18] or 6[19] weeks), two single-blind crossover studies found deflazacort (mean minimal effective dosage4.5 mg/day) to be equally effective as methylprednisolone (mean minimal effective dosage7.0 mg/day).

A number of longer-time (13 to 52 weeks) randomised studies have also evaluated the effectiveness of deflazacort as a treatment for rheumatoid arthritis in contrast to prednisone [20–23] or methylprednisolone [24]. These studies are in addition to the short-term trials mentioned above. Messina et al.’s primary goal was to compare how deflazacort and prednisone affected bone mineral content; relative efficacy was a secondary end-point. As a result, this trial’s inclusion requirements were somewhat different from those of the other investigations.

Additionally, only premenopausal women who had not before taken steroids or curative antirheumatic medications (DMARDs) were included in the study. They were enrolled. Auteri et al. [24] and Grey et al [22] likewise limited entrance to individuals who had not previously received corticosteroids but enrolled patients of either gender. Eberhardt et al [21], on the other hand, included only patients who needed corticosteroid treatment and authorised concurrent administration of DMARDs. All of these trials found that deflazacort enhanced the signs and symptoms of rheumatoid arthritis over time and was as effective as methylprednisolone or prednisone. Data from Auteri et al [24] and, in particular, Messina et al [20] are significant in that factors that potentially impact deflazacort efficacy, particularly concomitant medication, were closely controlled. Data from the trials of Eberhardt et al.[21] and Grey et al., [22] in which deflazacort was used as an addition to therapy with DMARDs and NSAIDs may be more typical of current clinical practice.

3.1.1 Juvenile Chronic Arthritis
Corticosteroids, like adult rheumatoid arthritis, are not regarded first-line therapy in children with juvenile chronic arthritis (JCA), mostly due to their proclivity to trigger adverse effects, most notably spinal crush fractures [25]. They are only indicated in cases of severe systemic disease or declining general health in the presence of increased disease activity despite treatment intervention (reviewed by Loftus et al [26].)

In one randomised trial, the efficacy of deflazacort and prednisone as treatments for corticosteroid-dependent JCA was examined. Corticosteroid dosages were titrated according to clinical necessity, resulting in daily dosages of 9.07 mg/day for deflazacort and 7.87 mg/day for prednisone (averaged over the entire trial period) for 31 children. During the research, primary therapy with 1 NSAID (all children) and DMARDs (13 deflazacort and 12 prednisone users) was maintained. The mean simple joint count decreased from 22 at baseline to 17.1 in deflazacort receivers but remained constant in prednisone recipients (baseline count 15). Mean length change was similar in both groups over a 12-month period, but net change in bodyweight and body surface space varied [0.8kg weight gain (3-month value) and 0.057m² increase in body surface area (mean annual trend) in prednisone recipients vs 0.5kg loss and 0.019m² increase in deflazacort recipients]. At baseline, 9 of 15 evaluable deflazacort receivers had roentgenographically confirmed vertebral crush fractures compared to 4 of 16 prednisone recipients. During the trial, two deflazacort recipients and one prednisone recipient had new crush fractures.[26] In an open-label extension of this research, 14 children received deflazacort medication for an additional year. During this period, deflazacort patients’ body weight gain returned, indicating that the reduction in body weight noticed in this group in the initial year of therapy was not due to increased disease activity. [27]

3.2 Asthma and Other Airways Diseases
The primary effect of corticosteroids in asthma patients is the lowering of airway inflammation because they are not bronchodilators. Patients with severe asthma who are refractory to inhaled bronchodilators or corticosteroids may benefit from long-term oral medication instead of short-term tapering therapy for acute flare-ups of a persistent asthma. The effectiveness of deflazacort in the latter capacity has only been examined in 2 investigations. As establishing prednisone and deflazacort having identical dosage was the main goal of both investigations, determining clinical efficacy was not given much attention. Only the final stage of the bigger of the two studies, which was conducted in three stages, evaluated the effectiveness of deflazacort and prednisone in a way that was clinically pertinent.

In fact, the results from this later stage of the investigation may have been undermined by the study design. Morning peak flow was 323.4 [compared to a baseline value (measured 12 weeks earlier) of 327.5] at the end of this phase for deflazacort receivers (n = 87) and 308.0 [compared to a baseline value of 303.1] for prednisone recipients (n = 104). Peak flow was not measured in a specific
unit. Similar trends were observed for forced expiratory volume in 1 second (FEV) values. The average daily doses for deflazacort and prednisone throughout this therapy period were 33.3 mg and 23.5 mg, respectively, for a ratio of 1: 1.4.[28]

The smaller trial, which was only available in abstract form, made a general assertion of therapeutic equivalency but no precise results data.[29]

A single trial was used to evaluate the effectiveness of deflazacort as a therapy for acute exacerbations of chronic asthma. Prednisone (first dosage 30 or 50mg; n = 15) or deflazacort (initial dose 30 or 60mg; n = 14) were given at random to 29 individuals whose FEV had decreased by at least 40%. Over the course of 15 to 18 days, the dosage of each medication was gradually decreased. Forced vital capacity (FVC) increased considerably in both groups (p 0.01 vs baseline; for deflazacort, from 76.1 to 81.4% of the theoretical value; for prednisone, from 71.5 to 81%). Peak expiratory flow rate, IFVC, and FEV all increased from baseline in a comparable manner.[30]

Despite the paucity of data, it seems that certain patients with chronic airway blockage may benefit significantly from treatment with glucocorticoids. Eosinophilia in the sputum rather than the blood may be a useful marker in some circumstances, while there are no specific indicators to determine which patients may respond favourably to corticosteroid treatment. [3] Deflazacort has been shown in two short-term early investigations to lessen airway blockage and relieve symptoms in individuals with chronic pulmonary illness (n = 20 in each study). [32,33]

3.3 Nephrotic Syndrome

Nephrotic syndrome, which is characterised by hypoproteinaemia, oedema, and significant proteinuria, can be brought on by a number of different disease processes (reviewed by Glassock & Brenner [34]). The most frequent underlying diseases are membranous glomerulonephritis and minimal lesion glomerulonephritis. Those with a tiny tumour among patients’ nephrotic syndrome, glucocorticoid therapy has been shown to increase the rate of spontaneous remission. It also has positive effects in patients with focal and segmental glomerulosclerosis, but it is less effective in patients with mesangial proliferative or membranous glomerulonephritis (reviewed by Glassock & Brenner [34]).

In three trials, the effectiveness of deflazacort in individuals with nephrotic syndrome was compared to that of prednisone. Deflazacort produced a considerably lower recurrence rate than prednisone (2 vs 11 patients; p = 0.025) for kids with recurrent idiopathic nephrotic syndrome, according to a 12-month double-blind trial by Lehnert et al. However, this study is only available in abstract form, and crucial methodological information, such as the drug dosages, is not provided. In several subsequent studies having deeper close-point assessment, deflazacort proved to be a minimum as efficacious as prednisone for individuals who had little evolve, membranoproliferative, focal segmental, or membrane glomerulonephritis (12-month double-blindling concurrent studies [37]).

Deflazacort and prednisone were given at beginning dosages of 96 versus 80 mg/day for three weeks by Olgaard et al. [37]; these dosages were subsequently gradually decreased to 24 versus 20 mg/day at the endpoint. Contrarily, Piccoli et al. [36] treated patients for 5 weeks with deflazacort 30 mg/day or prednisone 25 mg/day after initially administering intravenous methylprednisolone (3 x 500mg bolus doses).

In the earlier study [37] compared to the latter study [36], both medications resulted in higher decreases in 24-hour urine protein excretion (fig. 2). This could be a result of the varied ways that different types of nephrotic syndrome respond to corticosteroid therapy or the significantly larger beginning dosages that Olgaard et al. employed.[37]

3.4 Other application

Deflazacort's effectiveness has also been examined in clinical studies for a variety of other conditions, including symptoms of myasthenia gravis, systemic lupus erythematosus, sarcoidosis, thrombocytopenic purpura, following coronary or transplantation of the kidneys, uveitis, malignancies of the breast, vital blended cryoglobulinemia, Duchenne syndrome dystrophy, and safeguarding of remaining islet functioning in newly diagnosed diabetes that is insulin-dependent. Deflazacort's efficacy in comparative trials was typically on par with that of the comparator medicine, which was typically prednisone. Deflazacort considerably outperformed the placebo in all but one placebo-controlled experiment.

4. Tolerability

1064 patients were treated with deflazacort, 605 with prednisone, 88 with methylprednisolone, and 26 with betamethasone in 46 clinical investigations. The combined tolerability data show and 16.5% total prevalence of negative events in deflazacort users. [48]

In comparative trials, recipients of prednisone had a 20.5% overall prevalence of adverse events, compared to recipients of methylprednisolone who had a 32.7% prevalence and recipients of betamethasone who had a 15.3% incidence. The most frequent side effects of deflazacort therapy were gastrointestinal issues, including heartburn, gastritis, dyspepsia, nausea, and vomiting. [48]

The prevalence of gastrointestinal side effects was, however, less common in patients receiving deflazacort compared to those receiving prednisone and methylprednisolone. Other side effects suffered by deflazacort users included metabolic and nutritional issues, disruptions of the central and peripheral nervous systems, and psychological issues.

Cushing's syndrome was found to have developed in 8 of the 38 patients who were randomly assigned to prednisone against 7 of 38 randomized to deflazacort. 2 of 4 patients in the deflazacort group had pre-existing Cushing's syndrome related to 3 of 4 in the control group. Those who were on prednisone saw an aggravation of their symptoms. The sum of the Cushing’s symptom scores, however, showed that deflazacort receivers had a sum score of 52 whereas prednisone patients had a sum score of 116. Another study, only accessible in abstract form, found that giving patients receiving glucocorticoid therapy for rheumatoid arthritis prednisone instead of deflazacort cured the prednisone-induced Cushing's syndrome. However, no numerical information was provided. [49]
Dosage and Administration

According to the ailment being treated and its severity, corticosteroids are given at a wide range of dose levels. The standard dosage of Prednisone, the reference glucocorticoid, is of five to sixty mg per day. [67] Prednisone is stronger than deflazacort, which is typically used at dosages that are proportionately greater. Deflazacort is roughly twenty five percent less strong than prednisone in terms of total dosage, with a potency ratio of 1: 1.3, according to the findings of 7 trials of various designs, including 160 patients (including double blind crossover studies, paired sufferer studies, and between patient studies). For instance, 6mg of prednisone and 8mg of deflazacort produce biological responses that are identical.[68] Deflazacort with methylprednisolone had an estimated potency ratio of 1.6:1. [68]

Prednisone 40 mg/day was prescribed to individuals with asthmatic or bronchial pneumonia for a 2-week run-in phase with the goal to create an elevated initial glucocorticoid dose concentration. Another goal of a significant US trial was to compare the dosage equivalence of deflazacort and prednisone when taken orally. Out-patients were randomly assigned to receive either deflazacort (starting dosage 36 mg/day) or prednisone (initial dosage 30 mg/day) following this run-in period. The dosage of each medication was gradually decreased until the least effective dosage was attained. When at least two of the following things happened, it was determined that the minimal effective dosage had been reached: two of seven nights in a row the patient was awakened by asthma; a 20% reduction in morning peak expiratory flow (compared to prior evening value) on 4 out of 7 in succession mornings; or when the average patient-assessed symptom score fell for 7 days in a row below the average for the final 7 days of the run-in phase. Accordingly, the lowest effective dose of deflazacort was 27.2 mg/day (n = 45), compared to 20.5 mg/day for prednisone (n = 6), resulting in a ratio of 1.3: 1 [28].

6. Function of Deflazacort in Treatment

Systemic corticosteroid medication is only used when the advantages of treatment outweigh the hazards, of which osteoporosis is arguably the most serious. Although the exact cause of corticosteroid-induced osteoporosis is still unknown, one theory puts the blame on reduced the absorption of calcium by accelerated urine calcium excretion, and accelerated bone resorption (through stimulation of parathyroid function). According to two short-term studies examining deflazacort's effects on urinary calcium excretion, the drug has no effect and has no effect at all. However, a study comparing deflazacort to prednisone found that urinary calcium excretion increased in deflazacort recipients, albeit to a lesser extent than in prednisone recipients. Deflazacort reduces intestinal calcium absorption, according to several short-term investigations. These findings are intriguing, but because corticosteroid-induced osteoporosis is a long-term condition, it is possible that the treatment's short-term effects are not necessarily indicative of its long-term implications. To clearly understand the impact of deflazacort on these parameters, long-term research is necessary.[37] In support of this, short-term studies have demonstrated that deflazacort had less of an impact than prednisone on serum levels of osteocalcin, which may serve as a measure of skeletal cell activity.

Furthermore, in a brief 7-month trial, deflazacort had a lesser impact than prednisone on his to morphometrically assessed trabecular bone volume. Similar results were reported by two other 12-month trials; however, they measured bone mineral density using a less accurate technique (single or dual photon absorptiometry). Numerous indications for deflazacort's clinical application have been researched. However, as corticosteroid medication is only employed as a last resort, data are typically restricted to a small number of small-scale patient trials for each therapeutic area. The majority of the information on deflazacort's effectiveness has been gathered from rheumatoid arthritis patients. Even here, findings are only available from 4 trials that lasted the right amount of time to evaluate the effects of the medication for this indication, and the biggest of these had just 38 patients in each treatment arm. The fact that many studies focused on comparing the dose equivalence of deflazacort with other corticosteroids (often prednisone) while assessing relative efficacy was frequently a secondary end-point complicates analysis even more. Additionally, several comparison studies gave both medications at a chosen set ratio. Deflazacort dosage in some cases may have been too low in comparison to that of the comparator medication. Despite these drawbacks, deflazacort showed comparable effectiveness to prednisone and methylprednisolone in treating rheumatoid arthritis, as well as prednisone in treating individuals with nephrotic syndrome. There aren't enough facts to make any definite statements about the medication's effectiveness as an asthma treatment. Deflazacort was also more fruitful than placebo and as effective as the comparator medication (often prednisone) in comparison trials for a number of additional conditions, including Duchenne dystrophy, systemic lupus erythematosus, uveitis, and transplantation. Deflazacort medication may therefore result in fewer severe metabolic side effects than prednisone treatment. To prove this, additional long-term studies that titrate the dosage of each medicine to effect (rather than provide it at a fixed ratio) are needed. Deflazacort should typically only be used to treat individuals who are predisposed to, or who acquire, unacceptable metabolic sequelae when receiving corticosteroids until firm evidence are available. Nevertheless, despite the paucity of data, deflazacort should be carefully taken into account when considering corticosteroid therapy.

REFERENCES:


49. Deflazacort & gastro-intestinal side effects: a review. Unpublished data on file


